Selagine

Executive Summary

Selagine is a San Diego-based biotechnology spin-out from the University of Illinois at Chicago (UIC), founded in 2021 with a focus on developing novel therapeutics for ocular surface diseases driven by inflammatory, immunological, and infectious causes. The company addresses a significant unmet need in ophthalmology, where conditions such as dry eye disease, allergic conjunctivitis, and microbial keratitis lack effective and lasting treatments. Selagine’s platform leverages proprietary antibody and biologic approaches to modulate key pathways involved in ocular surface pathology, aiming to provide improved efficacy and tolerability over current standards of care. As an early-stage private company with no disclosed pipeline or funding details, Selagine is likely in the preclinical or discovery phase, advancing its lead candidate(s) toward investigational new drug (IND)-enabling studies. The company's academic origin suggests a strong scientific foundation, but its success hinges on securing capital and achieving key developmental milestones. With a lean profile and no public disclosures, Selagine represents a high-risk, high-reward opportunity in the ocular immunology space, pending further validation and clinical progress.

Upcoming Catalysts (preview)

• Q4 2026IND submission for lead ocular candidate30% success
• Q3 2026Series A financing round40% success
• Q2 2026Preclinical efficacy data readout50% success